Literature DB >> 12815490

Measurement and analysis of visual acuity in multicenter randomized clinical trials in the United States: findings from a survey.

Li Ming Dong1, Marta J Marsh, Barbara S Hawkins.   

Abstract

PURPOSE: To describe visual acuity (VA) testing and scoring methods used in multicenter randomized clinical trials in ophthalmology in the United States (USA) sponsored by the National Eye Institute (NEI).
METHODS: A survey was conducted among multicenter studies in the US that included one or more randomized clinical trials and were sponsored by the NEI, National Institutes of Health. To be included in the survey, a study had to have VA reported in one or more publications or patient eligibility based on VA, a majority of study subjects 13 years of age or older, and a patient population primarily or exclusively from the US. A standard survey form was completed for each study based on information presented in the study manual of procedures and publications. Findings were summarized and displayed with frequency distributions.
RESULTS: The survey included 24 studies, each with enrollment initiated in the period 1972 to 1999. VA was one of the study eligibility criteria for 19 (79%) studies, and VA or change in VA was the primary outcome in 12 (50%) studies. ETDRS charts have been employed in 16 of 19 studies initiated after the charts were published in 1982. All studies but one specified in the documents reviewed that VA testing was performed at multiple VA test distances. For studies that used ETDRS charts, methods of converting VA scores obtained at different test distances to a common scale fell into two categories: 11 studies used a method similar in nature to that first reported in the Macular Photocoagulation Study, and 7 studies used a method similar in nature to that first reported in the Krypton-Argon Regression of Neovascularization Study. conclusion The development of the ETDRS charts and a custom light box has led to more uniformity in VA test charts and chart illumination. However, details of VA measurement protocols vary widely from study to study. To assure comparable data across studies and ocular conditions, it would be useful to have a standard VA testing and scoring protocol with provisions for testing different levels of visual acuity that recommends a single method for converting scores from different test distances to a common scale and standard conversion of "off the chart" VA levels for calculation of means and changes in VA.

Entities:  

Mesh:

Year:  2003        PMID: 12815490     DOI: 10.1076/opep.10.3.149.15080

Source DB:  PubMed          Journal:  Ophthalmic Epidemiol        ISSN: 0928-6586            Impact factor:   1.648


  6 in total

1.  [Work sampling in ophthalmological clinical studies. A multicenter field study].

Authors:  D Böhringer; D Goos; T Ach; N Feltgen; M Fleckenstein; T Kohnen; K Lorenz; A Pielen; G Spital; B Wilhelm; S Böhringer; T Reinhard
Journal:  Ophthalmologe       Date:  2019-09       Impact factor: 1.059

2.  Comparison of the amblyopia treatment study HOTV and the electronic-early treatment of diabetic retinopathy study visual acuity protocols in amblyopic children aged 5 to 11 years.

Authors:  Eileen E Birch; Samara F Strauber; Roy W Beck; Jonathan M Holmes
Journal:  J AAPOS       Date:  2008-10-10       Impact factor: 1.220

3.  An assessment of the iPad as a testing platform for distance visual acuity in adults.

Authors:  J M Black; R J Jacobs; G Phillips; L Chen; E Tan; A Tran; B Thompson
Journal:  BMJ Open       Date:  2013-06-20       Impact factor: 2.692

4.  Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis.

Authors:  Pierre-Henry Gabrielle; Vuong Nguyen; Jennifer J Arnold; Sanjeeb Bhandari; Francesco Viola; Odette A M Tigchelaar-Besling; Gonzaga Garay-Aramburu; Louise O'Toole; Chui Ming Gemmy Cheung; Daniel Barthelmes; Catherine Creuzot-Garcher; Mark Gillies
Journal:  Transl Vis Sci Technol       Date:  2021-11-01       Impact factor: 3.283

5.  HAS SNELLEN CHART LOST THE BATTLE TO ETDRS IN CATARACT SURGERY VISUAL ACUITY EVALUATION?

Authors:  Sanja Petrović Pajić; Tiana Petrović; Milenko Stojković; Slađana Anđelić
Journal:  Acta Clin Croat       Date:  2022-02       Impact factor: 0.780

6.  Monitoring progression of retinitis pigmentosa: current recommendations and recent advances.

Authors:  Moreno Menghini; Jasmina Cehajic-Kapetanovic; Robert E MacLaren
Journal:  Expert Opin Orphan Drugs       Date:  2020-03-02       Impact factor: 0.694

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.